SAB Biotherapeutics’ (SABS) “Buy” Rating Reiterated at HC Wainwright

SAB Biotherapeutics (NASDAQ:SABS)‘s stock had its “buy” rating reiterated by research analysts at HC Wainwright in a note issued to investors on Tuesday,Benzinga reports. They presently have a $6.00 price objective on the stock. HC Wainwright’s price target would indicate a potential upside of 341.18% from the stock’s current price.

Separately, Chardan Capital reissued a “buy” rating and set a $25.00 target price on shares of SAB Biotherapeutics in a report on Wednesday, January 29th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, SAB Biotherapeutics currently has a consensus rating of “Buy” and an average price target of $12.40.

SAB Biotherapeutics Stock Down 8.1 %

NASDAQ:SABS opened at $1.36 on Tuesday. The stock has a 50 day simple moving average of $1.98 and a 200 day simple moving average of $2.83. SAB Biotherapeutics has a 1-year low of $1.36 and a 1-year high of $5.01. The company has a debt-to-equity ratio of 0.09, a current ratio of 3.69 and a quick ratio of 3.69.

Institutional Investors Weigh In On SAB Biotherapeutics

Large investors have recently added to or reduced their stakes in the stock. HB Wealth Management LLC raised its holdings in SAB Biotherapeutics by 118.6% in the 4th quarter. HB Wealth Management LLC now owns 237,400 shares of the company’s stock valued at $982,000 after acquiring an additional 128,800 shares in the last quarter. Geode Capital Management LLC raised its stake in SAB Biotherapeutics by 18.8% in the fourth quarter. Geode Capital Management LLC now owns 80,234 shares of the company’s stock valued at $307,000 after purchasing an additional 12,692 shares in the last quarter. Diadema Partners LP acquired a new position in SAB Biotherapeutics in the fourth quarter valued at about $114,000. Kovitz Investment Group Partners LLC bought a new stake in SAB Biotherapeutics during the third quarter worth about $52,000. Finally, Northern Trust Corp acquired a new stake in SAB Biotherapeutics during the fourth quarter worth about $43,000. Institutional investors and hedge funds own 7.82% of the company’s stock.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.